Spirig Pharma AG acquired by Galderma Pharma SA

On December 12, 2012, Galderma Pharma SA, a global specialty pharmaceutical company focused on dermatology, announced having entered into a purchase agreement to acquire Spirig Pharma AG, a leading company in the development, production, and marketing of dermatological products with the leading brands Excipial, Daylong and Daylong Actinica. The transaction is expected to close in the first quarter of 2013.

Lenz & Staehelin acted as legal advisor to the selling shareholders of Spirig Pharma AG in this transaction. The team was led by Stephan Erni (Corporate and M&A) and consisted of Philipp Frech and Eric Olivier Meier (both Corporate and M&A), Marcel Meinhardt and Felix Prümmer (both Competition) as well as Heini Rüdisühli, Franziska Stadtherr-Glättli and Stefan Schwaller (all Tax).

Published: 17 December 2012